-
公开(公告)号：US20220184179A1
公开(公告)日：2022-06-16
申请号：US17511183
申请日：2021-10-26
发明人： Joe Pirrello , Eben Tessari , Luis Carvajal , Annalisa D'andrea
摘要： The present invention provides, among other things, a method of treating cancer comprising administering a GM-CSF antagonist to the patient in need of treatment, wherein the administration of the GM-CSF antagonist improves, stabilizes or reduces one or more symptoms of the cancer in the patient. The present invention also provides, among other things, a method of inhibiting progression of cancer in a patient suffering from cancer with one or more mutations in KRAS, NRAS and/or JAK2 comprising administering a GM-CSF antagonist to the patient.
-
公开(公告)号：US20240117058A1
公开(公告)日：2024-04-11
申请号：US18485116
申请日：2023-10-11
发明人： Joe Pirrello , John Paolini , Eben Tessari
IPC分类号： C07K16/28 , A61K31/573 , A61K31/685 , A61P31/14
CPC分类号： C07K16/2866 , A61K31/573 , A61K31/685 , A61P31/14 , A61K2039/545
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
公开(公告)号：US11325979B2
公开(公告)日：2022-05-10
申请号：US17324931
申请日：2021-05-19
发明人： Joe Pirrello , John Paolini , Eben Tessari
IPC分类号： C07K16/28 , A61P31/14 , A61K31/573 , A61K31/685 , A61K39/00
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
公开(公告)号：US20210284745A1
公开(公告)日：2021-09-16
申请号：US17324931
申请日：2021-05-19
发明人： Joe Pirrello , John Paolini , Eben Tessari
IPC分类号： C07K16/28 , A61K31/685 , A61K31/573 , A61P31/14
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
公开(公告)号：US20210284744A1
公开(公告)日：2021-09-16
申请号：US17201698
申请日：2021-03-15
发明人： Joe Pirrello , John Paolini , Eben Tessari
摘要： The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
